SEC Form DEFA14A filed by ResMed Inc.

$RMD
Medical/Dental Instruments
Health Care
Get the next $RMD alert in real time by email
DEFA14A 1 resmedinc_formdefa2024-n.htm DEFA14A resmedinc_formdefa2024-n
US-DOCS\135492894.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant  Filed by a Party other than the Registrant  Check the appropriate box:  Preliminary Proxy Statement  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  Definitive Proxy Statement  Definitive Additional Materials  Soliciting Material Pursuant to § 240.14A-12 (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): Payment of Filing Fee (Check all boxes that apply):  No fee required.  Fee paid previously with preliminary materials.  Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.


 
Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V57723-P18666 RESMED INC. 9001 SPECTRUM CENTER BLVD. SAN DIEGO, CA 92123 ATTN: AMY WAKEHAM RESMED INC. 2024 Annual Meeting Date: November 20, 2024 Time: 4:30 p.m. (US Pacific Time) November 21, 2024 Time: 8:30 a.m. (Singapore Time); 11:30 a.m. (Australian Eastern Time) Live webcast: Meeting live via the internet-please visit www.virtualshareholdermeeting.com/RMD2024 *Please check the meeting materials for any special requirements for meeting attendance. You invested in RESMED INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. Important notice regarding the availability of proxy materials for the stockholder meeting to be held on November 20, 2024 (US Time)/ November 21, 2024 (Singapore and Australian Time). Get informed before you vote View the Notice, Proxy Statement, and Form 10-K online at www.ProxyVote.com, OR you can receive a free paper or email copy of the materials. If you would like to request a copy of the materials for this and/or future stockholder meetings, you may (1) visit http://www.ProxyVote.com, (2) call 1-800-579-1639, or (3) send an email to sendmaterial@ProxyVote.com, by November 6, 2024. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Virtually at: www.virtualshareholdermeeting.com/RMD2024 Vote Virtually at the Meeting* November 20, 2024 at 4:30 p.m. (US Pacific Time) November 21, 2024 at 8:30 a.m. (Singapore Time); 11:30 a.m. (Australian Eastern Time)


 
Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V57724-P18666 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. 1. Elect 11 directors, each to serve until our 2025 annual meeting and until their successors are elected and qualified. The nominees for election as directors at the 2024 annual meeting are: Continuing directors: 1a. Carol Burt For 1b. Christopher DelOrefice For 1c. Jan De Witte For 1d. Karen Drexler For 1e. Michael Farrell For 1f. Peter Farrell For 1g. Harjit Gill For 1h. John Hernandez For 1i. Richard Sulpizio For 1j. Desney Tan For 1k. Ronald Taylor For 2. Ratify our selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2025. For 3. Approve, on an advisory basis, the compensation paid to our named executive officers, as disclosed in the proxy statement (“say-on-pay”). For


 
Get the next $RMD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RMD

DatePrice TargetRatingAnalyst
3/19/2025$280.00Overweight
Morgan Stanley
3/19/2025Overweight
Morgan Stanley
1/16/2025Buy
Goldman
1/10/2025$252.00Neutral
Piper Sandler
12/13/2024$250.00Hold
Stifel
9/24/2024$280.00Outperform
Robert W. Baird
9/18/2024$180.00Peer Perform → Underperform
Wolfe Research
9/4/2024Buy → Hold
Needham
More analyst ratings

$RMD
Press Releases

Fastest customizable press release news feed in the world

See more
  • New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer

    SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark meta-analysis in The Lancet Respiratory Medicine, demonstrating that CPAP therapy significantly reduces the risk of death for people with obstructive sleep apnea (OSA). Analyzing data from over 1 million sleep apnea patients worldwide, the study provides the strongest evidence to date that CPAP therapy not only alleviates OSA symptoms but can also prolong life. OSA affects over one billion people worldwide,1 with over 80% of cases undiagnosed and untreated.2 This chron

    $RMD
    Medical/Dental Instruments
    Health Care
  • Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution

    SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a comprehensive brand evolution designed to unify its brand portfolio to serve more people and healthcare providers worldwide and reflect growing direct to consumer engagement. For 35 years, Resmed has pioneered innovations in respiratory therapy, including CPAP therapy and digital health solutions. The company's last major brand update in 2014 marked its shift to connectivity, introducing cloud-connected medical devices that revolutionized sleep apnea therapy. Today, Resmed is taking the next step –

    $RMD
    Medical/Dental Instruments
    Health Care
  • ResMed's Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep

    7 out of 10 employed respondents have called in sick at least once in their career due to poor sleep.18% of couples reported sleeping in separate rooms due to snoring and restlessness.Women report fewer quality sleep nights and more difficulties falling asleep than men. SAN DIEGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD)), a global health technology leader focused on sleep, breathing, and care delivered in the home, today unveiled the findings of its fifth annual Global Sleep Survey. With insights from 30,026 respondents across 13 markets, the study underscores a widespread global sleep crisis, with people losing an average of nearly three nights of restorative sleep

    $RMD
    Medical/Dental Instruments
    Health Care

$RMD
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$RMD
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$RMD
SEC Filings

See more

$RMD
Leadership Updates

Live Leadership Updates

See more
  • Jan De Witte joins GHO Capital as Operating Partner

    Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr

    $IART
    $RMD
    Medical/Dental Instruments
    Health Care
  • Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

    NEW YORK and MELBOURNE, Australia, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines today announced the appointment of Alison Wimms, Ph.D. as an advisor to its newly formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board where she will represent ResMed. Dr. Wimms brings two decades of sleep medicine industry and research expertise to her advisory role at Incannex. Dr. Wimms holds a Doctor of Philosophy (Ph.D.) in Medicine, and Master of Medicine (Sleep Medicine) and Bachelor of Science degrees from the University of Sydney. "Incannex's

    $IXHL
    $RMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
  • ResMed Expands its Board of Directors and Appoints Healthcare Executive and Seasoned Finance Leader Christopher DelOrefice to its Board

    DelOrefice is the Chief Financial Officer at BD, one of the largest global MedTech companies in the worldBoard appointment brings over 30 years of strategic and operational finance expertise SAN DIEGO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced it has expanded the size of its board of directors to 11 and has elected Christopher DelOrefice to the board, effective immediately. Mr. DelOrefice was appointed during ResMed's regularly scheduled board meeting on August 15, 2024, and will stand for re-election with the rest of ResMed's directors at its annual meeting on November 21, 2024. Mr. DelOrefice has also been appointed as a member of ResMed's board au

    $RMD
    Medical/Dental Instruments
    Health Care

$RMD
Financials

Live finance-specific insights

See more
  • ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2025

    Year-over-year revenue grows 10%, operating profit up 52%, non-GAAP operating profit up 19%Operating cash flow of $309 million Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended December 31, 2024. Second Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 10% to $1.3 billion; up 10% on a constant currency basis Gross margin improved 300 bps to 58.6%; non-GAAP gross margin improved 230 bps to 59.2%Income from operations increased 52%; non-GAAP income from operations

    $RMD
    Medical/Dental Instruments
    Health Care
  • ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025

    SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the second quarter of fiscal year 2025 on Thursday, January 30, 2025, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: • Location:https://investor.resmed.com• Date:Thursday, January 30, 2025• Time:1:30 p.m. PST / 4:30 p.m. EST• International:London, Thursday, January 30, 2025, 9:30 p.m. GMT Sydney, Friday, January 31, 2025, 8:30 a.m. AEDT   Please no

    $RMD
    Medical/Dental Instruments
    Health Care
  • ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2025

    Year-over-year revenue grows 11%, operating profit up 34%, non-GAAP operating profit up 27%Operating cash flow of $326 million Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE:RMD, ASX: RMD))) today announced results for its quarter ended September 30, 2024. First Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 11% to $1.2 billion; up 11% on a constant currency basis Gross margin improved 420 bps to 58.6%; non-GAAP gross margin improved 320 bps to 59.2%Income from operations increased 34%; non-GAAP income from operation

    $RMD
    Medical/Dental Instruments
    Health Care

$RMD
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more